Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$1.93
-$0.03(-1.53%)
At close: 4:00 PM EST
$1.93
-$0.03(-1.53%)
Day’s Range― - ―
52-Week Range$0.29 - $14.14
Previous Close$0.14
Volume19.82K
Average Volume (3M)2.54M
Market Cap
$2.29M
Enterprise Value-$3.69M
Total Cash (Recent Filing)$3.93M
Total Debt (Recent Filing)$26.00K
Price to Earnings (P/E)―
Beta3.02
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding6,259,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit167.56
Enterprise Value/Ebitda0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progression: IDE SubmissionFiling an IDE to begin U.S. clinical trials represents a structural move from preclinical to clinical development. If cleared, it enables generation of pivotal human data needed for regulatory approvals and commercial entry, materially advancing commercialization prospects.
Peer‑reviewed Preclinical ValidationRobust, peer‑reviewed in‑vivo results and prior human data materially de‑risk the technology platform. Durable scientific validation increases credibility with regulators, clinicians, and partners, supporting a defensible clinical pathway and potential differentiation in CGM market.
Low Absolute Debt And Liability ManagementLow absolute debt reduces creditor solvency pressure; converting portions of promissory notes to equity eases near‑term cash obligations. Structurally this lowers short‑term default risk and can extend runway while clinical programs advance, improving financing flexibility.
Bears Say
No Meaningful Revenue; High Cash BurnPersistent negative operating and free cash flow with no revenue base forces ongoing external financing. Over 2–6 months this structural cash consumption increases dilution risk, constrains investment in trials/commercialization, and heightens dependence on capital markets.
Negative Stockholders' EquityNegative equity reflects accumulated losses and weakens financial flexibility. Structurally it hampers ability to secure unsecured financing, may trigger covenant/listing thresholds, and reduces confidence of partners and suppliers over the medium term.
Nasdaq Deficiency Notices And Delisting RiskActive deficiency notices create sustained listing uncertainty that can restrict access to U.S. capital markets, deter institutional and strategic partners, and complicate fundraising or collaborations—material constraints for a pre‑revenue medical device developer.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.29 and its highest was $14.14 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $2.29M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Aug 13, 2026 which is in 34 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on May 14, 2026. The company reported -$2.646 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.646.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 6,259,279 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$2.646 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.84%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
Technical Analysis
Ownership Overview
0.18% Insiders
0.18% Mutual Funds
0.80% Other Institutional Investors
98.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---